Scisparc

SPRC · NASDAQ

$1.33−$0.07 (−5.00%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $1.40

About SPRC

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees: 2
Headquarters: TEL AVIV-YAFO
Listed: Dec 22, 2021
Sector: Health Care
Industry: Pharmaceuticals
Website: scisparc.com

Leadership

Scisparc executives
Name	Title	Since	Age
Itschak Shrem	—	2020	74
Amitay Weiss	—	2020	62
Oz Adler	—	—	39
Adi Zuloff-Shani	—	—	56
Moshe Revach	—	—	44
Liat Sidi	—	—	50
Alon Dayan	—	—	48
Prof. Ari Shamiss	—	—	62
Amnon Shay	—	—	58
Lior Vider	—	—	44

Similar companies

Companies in the same industry as Scisparc

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.